Response to Treatment Before Surgery in Locally Advanced Thyroid Cancer
Observes how people with advanced thyroid cancer respond to drug treatment before surgery.
Plain-language title generated from the registry record
Registry title: Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Key facts
- Where
- Fuzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 80 years old?
Source: NCT07419932, who can take part
Where in China
- Fujian Medical University Union HospitalFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fujian Medical University
- Trial code
- NCT07419932
- Record updated
- 19 February 2026
- Original description
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.Read full original descriptionShow less
Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.
Inclusion: Age ≥ 14 years at enrollment; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC); LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board; For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team; Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Normal function of major organs; Written informed consent obtained.
Exclusion: Patients who refuse tumor tissue biopsy or surgery; Prior thyroid or major neck surgery; Concurrent active malignancies; History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan; Uncontrolled systemic diseases, including diabetes, hypertension, etc; Pregnancy or breastfeeding.